Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)LeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares Repurchased
Ratios

Amphastar Pharmaceuticals (AMPH) Receivables - Net (2016 - 2025)

Amphastar Pharmaceuticals has reported Receivables - Net over the past 13 years, most recently at $143.6 million for Q4 2025.

  • Quarterly results put Receivables - Net at $143.6 million for Q4 2025, up 5.33% from a year ago — trailing twelve months through Dec 2025 was $143.6 million (up 5.33% YoY), and the annual figure for FY2025 was $143.6 million, up 5.33%.
  • Receivables - Net for Q4 2025 was $143.6 million at Amphastar Pharmaceuticals, down from $146.8 million in the prior quarter.
  • Over the last five years, Receivables - Net for AMPH hit a ceiling of $146.8 million in Q3 2025 and a floor of $67.9 million in Q2 2021.
  • Median Receivables - Net over the past 5 years was $109.8 million (2023), compared with a mean of $108.8 million.
  • Biggest five-year swings in Receivables - Net: decreased 6.12% in 2022 and later surged 54.33% in 2023.
  • Amphastar Pharmaceuticals' Receivables - Net stood at $78.8 million in 2021, then increased by 12.69% to $88.8 million in 2022, then grew by 29.43% to $114.9 million in 2023, then grew by 18.57% to $136.3 million in 2024, then rose by 5.33% to $143.6 million in 2025.
  • The last three reported values for Receivables - Net were $143.6 million (Q4 2025), $146.8 million (Q3 2025), and $133.0 million (Q2 2025) per Business Quant data.